Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
W.V. Epstein.
Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience.
Arthritis Rheum, 39 (1996), pp. 1773-1780
[2.]
E.L. Matteson, D.E. Yocum, E.W. St Clair, A.A. Achkar, M.S. Thakor, M.R. Jacobs, et al.
Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection.
Arthritis Rheum, 38 (1995), pp. 1187-1193
[3.]
A. Protheroe, J.C. Edwards, A. Simmons, K. Maclennan, P. Selby.
Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma.
Rheumatology, 38 (1999), pp. 1150-1152
[4.]
J.C. Edwards, G. Cambridge.
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.
Rheumatology, 40 (2001), pp. 205-211
[5.]
Z. Zhang, S.L. Bridges Jr.
Pathogenesis of rheumatoid arthritis: role of B lymphocytes.
Rheum Dis Clin North Am, 27 (2001), pp. 335-353
[6.]
E. Keystone.
B Cell targeted therapies.
Arthritis Research & Therapy, 7 (2005), pp. S13-S18
[7.]
G.J. Silverman.
Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic.
Artritis Rheum, 52 (2005), pp. 371-377
[8.]
R.J. Looney, J. Anolik, I. Sanz.
B cells as therapeutic targets for rheumatic diseases.
Curr Opin Rheumatol, 16 (2004), pp. 180-185
[9.]
J.M. Kremer, M. Dougados, P. Emery, P. Durez, J. Sibilia, W. Shergy.
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
Arthritis Rheum, 52 (2005), pp. 2263-2271
[10.]
Genentech Inc, IDEC, F Hoffmann-La Roche Ltd. Investigator's Brochure for Rituximab (Ro 45-2294) in autoimmune disease, fourth Edition, June 2005.
[11.]
R. Eisenberg, R.J. Looney.
The therapeutic potential of anti-CD20 “What do B-cells do?”.
Clin Immunol, 117 (2005), pp. 207-213
[12.]
J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, et al.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
N Engl J Med, 350 (2004), pp. 2572-2581
[13.]
R.J. Looney, J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, L.J. Arend, et al.
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
Arthritis Rheum, 50 (2004), pp. 2580-2589
[14.]
J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, I. Sanz, J. Rosenblatt, et al.
The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.
Arthritis Rheum, 48 (2003), pp. 455-459
[15.]
M.J. Leandro, G. Cambridge, J.C. Edwards, M.R. Ehrestein, D.A. Isemberg.
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
Rheumatology, 44 (2005), pp. 1542-1545
[16.]
E. Kimby.
Tolerability and safety of rituximab (MabThera).
Cancer Treat Rev, 31 (2005), pp. 456-473
[17.]
H. Tahir, J. Rohrer, A. Bhatia, W.A. Wegener, D.A. Isenberg.
Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab.
Rheumatology (Oxford), 44 (2005), pp. 561-562
[18.]
Wolbink G, Vis M, Vrieze H, O Stapel S, Lems WF, Aarden L. Human anti chimeric antibodies (HACA) directed against infliximab do not cross react with adalimumab or rituximab. Abstract 877, presentado en ACR. San Diego Noviembre 11-17 2005.
[19.]
M. Catuogno, S. Rezai, R. Priori, L. Magrini, G. Valesini.
Serum sickness associated with rituximab in a patient with hepatitis C.
Rheumatology (Oxford), 44 (2005), pp. 406
[20.]
T. Hamaki, M. Kami, E. Kusumi, J. Ueyama, S. Miyakoshi, S. Morinaga, et al.
Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab.
Am J Hematol, 68 (2001), pp. 292-294
[21.]
M. Kami, T. Hamaki, N. Murashige, Y. Kishi, E. Kusumi, K. Yuji, et al.
Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection.
Hematol J, 4 (2003), pp. 159-162
[22.]
A. Klepfish, A. Stationer, L. Shvidel, M. Shtalrid, M. Haran, Z. Bentwich, et al.
Successful treatment of aggressive HIV-associated non-Hodgkin's lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option.
Leuk Lymphoma, 44 (2003), pp. 349-351
[23.]
Fleischmann RM, Pavelka K, Baldassare AR, Martin-Mola E, Chatpar PC, Nash PT, et al. Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis. Abstract 264. ACR San Diego. Noviembre 2005.
[24.]
S.B. Cohen, M. Greenwald, M.R. Dougados, P. Emery, R. Furie, T.M. Shaw, et al.
Efficacy and safety of rituximab in active R A patients who experienced an inadequate response to one or more anti-TNF-α therapies (REFLEX Study). Abstract 1830.
ACR San Diego, (2005),
[25.]
P.P. Sfikakis, J.N. Boletis, S. Lionaki, V. Vigklis, K.G. Fragiadaki, A. Iniotaki, et al.
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
Arthritis Rheum, 52 (2005), pp. 501-513
[26.]
R. Stasi, A. Pagano, E. Stipa, S. Amadori.
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
Blood, 98 (2001), pp. 952-957
[27.]
Levine TD Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005; 52:601-7.
[28.]
K.A. Keogh, M.E. Wylam, J.H. Stone, U. Specks.
Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.
Arthritis Rheum, 52 (2005), pp. 262-268
[29.]
J. Higashida, T. Wun, S. Schmidt, S.M. Naguwa, J.M. Tuscano.
Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
J Rheumatol, 32 (2005), pp. 2109-2115
[30.]
G. Cambridge, W. Stohl, M.J. Leandro, T.S. Migone, D.M. Hilbert, J.C. Edwards.
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Arthritis Rheum, 54 (2006), pp. 723-732
Copyright © 2006. Elsevier España S.L. Barcelona
